{"links":{"html":"https://www.erudio.com/reports/platon-nct03784755","json":"https://www.erudio.com/reports/platon-nct03784755.json","markdown":"https://www.erudio.com/reports/platon-nct03784755.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"platon-03784755"}},"request":"https://www.erudio.com/contact?report=platon-03784755"},"offer":{"cited_commentary_sources":31,"verified_hcp_statements":445,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":47,"optional":true,"price_per_verified_person_usd":15,"price_usd":705,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"platon-nct03784755"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=platon-03784755","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/platon-nct03784755","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T07:00:31.225694Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Failure-free Survival"},{"claim_count":26,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":10,"title":"Secondary endpoints"},{"claim_count":47,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":12,"title":"Population and setting"},{"claim_count":39,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":13,"title":"The comparison"},{"claim_count":22,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":52,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":14,"title":"Design and conduct"},{"claim_count":26,"coverage":"discussed","id":"A1","source_count":4,"title":"PSMA stage migration, prognostic work-up and access-dependent systemic treatment"},{"claim_count":39,"coverage":"discussed","id":"A2","source_count":7,"title":"Systemic intensification versus selective ADT-sparing or delayed-treatment approaches"},{"claim_count":51,"coverage":"discussed","id":"A3","source_count":2,"title":"Equivocal PET findings and the decision to observe, classify or treat recurrent disease"},{"claim_count":78,"coverage":"discussed","id":"A4","source_count":2,"title":"Occupational consequences, patient priorities and intermittent treatment in the pilot case"},{"claim_count":24,"coverage":"discussed","id":"A5","source_count":3,"title":"Lesion-only versus pelvic-field treatment and selective roles for surgery"},{"claim_count":11,"coverage":"discussed","id":"A6","source_count":1,"title":"Prostate-primary radiation dose, fractionation and disputed schedule interpretations"},{"claim_count":16,"coverage":"discussed","id":"A7","source_count":2,"title":"Lutetium as an MDT partner, mechanistic uncertainty and prospective priming strategies"},{"claim_count":45,"coverage":"discussed","id":"A8","source_count":7,"title":"Treatment access, trial acceptability and the economics of comparator selection"}],"counts":{"cited_sources":31,"claims_by_expression_type":{"comparison":26,"experience":49,"interpretation":76,"opinion":136,"primary_context":1,"question":58,"restatement":37,"uncertainty":16,"unspecified":46},"claims_by_kind":{"source_observation":445},"clinician_statements":108,"evidence_units":499,"findings":12,"organisational_accounts":2,"people_cited":51,"people_identity_verified":47,"people_total":51,"screened_sources":47,"verified_claims":445},"findings_index":[{"id":"F1","structure":{"claims":81,"claims_by_group":{"comparisons":4,"experience":6,"questions":12,"restated":15,"views":44},"has_counterview":true,"limitations":3,"links":{"context":10,"support":86},"ma_question":true,"named_voices":30,"passages":77,"sources":14,"sources_by_kind":{"commentary":11,"media":3}},"title":"Whether MDT is routine care remains contested, with endpoint choice central to the disagreement"},{"id":"F2","structure":{"claims":37,"claims_by_group":{"comparisons":5,"experience":5,"questions":6,"restated":6,"views":15},"has_counterview":true,"limitations":3,"links":{"context":4,"support":43},"ma_question":true,"named_voices":13,"passages":38,"sources":11,"sources_by_kind":{"commentary":8,"media":3}},"title":"PLATON is valued for testing MDT beyond contemporary systemic therapy, but its clinical impact remains prospective"},{"id":"F3","structure":{"claims":27,"claims_by_group":{"comparisons":0,"experience":4,"questions":7,"restated":2,"views":14},"has_counterview":true,"limitations":3,"links":{"context":2,"support":28},"ma_question":true,"named_voices":10,"passages":23,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"PSMA staging can accelerate systemic treatment and funding access without resolving whether the management change improves outcomes"},{"id":"F4","structure":{"claims":49,"claims_by_group":{"comparisons":4,"experience":6,"questions":13,"restated":3,"views":23},"has_counterview":true,"limitations":4,"links":{"context":7,"support":65},"ma_question":true,"named_voices":7,"passages":52,"sources":8,"sources_by_kind":{"commentary":5,"media":3}},"title":"Selection cannot rest on technical targetability alone: biology, burden, imaging completeness and marrow reserve matter"},{"id":"F5","structure":{"claims":23,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":5,"views":14},"has_counterview":true,"limitations":4,"links":{"context":4,"support":27},"ma_question":true,"named_voices":7,"passages":25,"sources":5,"sources_by_kind":{"commentary":3,"media":2}},"title":"Combination-treatment enthusiasm coexists with selective efforts to defer or limit systemic therapy"},{"id":"F6","structure":{"claims":51,"claims_by_group":{"comparisons":0,"experience":0,"questions":7,"restated":17,"views":27},"has_counterview":true,"limitations":4,"links":{"context":14,"support":61},"ma_question":true,"named_voices":2,"passages":56,"sources":2,"sources_by_kind":{"media":2}},"title":"An equivocal low-PSA recurrence exposes disagreement over scanning, metastatic classification and the threshold to treat"},{"id":"F7","structure":{"claims":78,"claims_by_group":{"comparisons":7,"experience":14,"questions":13,"restated":20,"views":24},"has_counterview":true,"limitations":3,"links":{"context":11,"support":114},"ma_question":true,"named_voices":2,"passages":98,"sources":2,"sources_by_kind":{"media":2}},"title":"The pilot case makes licensing, evidence applicability and treatment interruption consequential parts of the MDT decision"},{"id":"F8","structure":{"claims":24,"claims_by_group":{"comparisons":3,"experience":2,"questions":3,"restated":7,"views":9},"has_counterview":true,"limitations":3,"links":{"context":0,"support":46},"ma_question":true,"named_voices":4,"passages":39,"sources":3,"sources_by_kind":{"media":3}},"title":"Occult pelvic disease challenges lesion-only treatment, while symptoms and anatomy preserve selective surgical roles"},{"id":"F9","structure":{"claims":21,"claims_by_group":{"comparisons":0,"experience":9,"questions":1,"restated":3,"views":8},"has_counterview":true,"limitations":3,"links":{"context":1,"support":22},"ma_question":true,"named_voices":10,"passages":22,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Perceived low treatment burden does not remove radiation complications or barriers to SBRT access"},{"id":"F10","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":0,"views":9},"has_counterview":true,"limitations":2,"links":{"context":1,"support":13},"ma_question":true,"named_voices":8,"passages":13,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Prostate-primary dose discussions prioritize low toxicity but leave room for definitive treatment in a solitary-metastasis scenario"},{"id":"F11","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":6,"views":9},"has_counterview":true,"limitations":3,"links":{"context":1,"support":27},"ma_question":true,"named_voices":1,"passages":26,"sources":2,"sources_by_kind":{"media":2}},"title":"Lutetium is discussed as an alternative systemic partner and a sequencing opportunity, not established proof of synergy"},{"id":"F12","structure":{"claims":34,"claims_by_group":{"comparisons":1,"experience":1,"questions":9,"restated":1,"views":22},"has_counterview":true,"limitations":3,"links":{"context":1,"support":36},"ma_question":true,"named_voices":15,"passages":37,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Randomization acceptability, systemic-treatment comparability and funding complicate evidence generation"}],"medical_affairs_question":"Which patients gain enough from adding MDT to justify its timing, systemic-treatment burden and local-treatment risks, and which outcomes would demonstrate that value?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Routine MDT: the disagreement concerns sufficient benefit, not merely activity"},{"id":"section-2","level":3,"title":"Signals, anecdotes and treatment burden do not settle broad adoption"},{"id":"section-3","level":3,"title":"Endpoints and population differences carry the clinical dispute"},{"id":"section-4","level":3,"title":"Cross-cancer skepticism is an argument for testing, not a prostate result"},{"id":"section-5","level":2,"title":"PLATON's anticipated contribution is incremental MDT benefit on a modern backbone"},{"id":"section-6","level":2,"title":"PSMA-driven treatment changes: earlier detection, biological risk and access are intertwined"},{"id":"section-7","level":3,"title":"A management change is not automatically a beneficial change"},{"id":"section-8","level":2,"title":"Selection beyond the number of targetable lesions"},{"id":"section-9","level":2,"title":"Combination treatment and the separate question of avoiding systemic exposure"},{"id":"section-10","level":2,"title":"Equivocal PET findings do not settle the need for immediate treatment"},{"id":"section-11","level":2,"title":"Licensing changes the pilot case's treatment trade-offs"},{"id":"section-12","level":3,"title":"The evidence sent for licensing matters"},{"id":"section-13","level":3,"title":"Interruption is offered, not reported as undertaken"},{"id":"section-14","level":2,"title":"Pelvic coverage and selective surgery address different sources of undertreatment"},{"id":"section-15","level":3,"title":"Radiation-dominant practice is not a categorical rejection of surgery"},{"id":"section-16","level":2,"title":"Convenience, radiation harm and reimbursement need separate interpretation"},{"id":"section-17","level":3,"title":"Payer barriers expose disagreement over which benefits count"},{"id":"section-18","level":2,"title":"Primary-prostate fractionation reflects treatment intent, not a settled dose advantage"},{"id":"section-19","level":2,"title":"Lutetium enthusiasm separates treatment choice from unproven mechanism"},{"id":"section-20","level":2,"title":"Trial feasibility depends on equipoise, comparable treatment and what the endpoint measures"},{"id":"section-21","level":3,"title":"Off-trial access can undermine willingness to randomize"},{"id":"section-22","level":3,"title":"Systemic exposure must remain interpretable alongside MDT"},{"id":"section-23","level":3,"title":"Comparator choice remains part of the clinical controversy"},{"id":"section-24","level":3,"title":"Funding affects which clinically useful comparisons can be run"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, na","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2}],"id":"T1","label":"Primary endpoint: Failure-free Survival"},{"findings":[{"id":"F1","shared_claims":19},{"id":"F2","shared_claims":3},{"id":"F9","shared_claims":2},{"id":"F12","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":39},{"id":"F5","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":12},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":12},{"id":"F6","shared_claims":2},{"id":"F12","shared_claims":7}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F4","shared_claims":6},{"id":"F8","shared_claims":3},{"id":"F9","shared_claims":10},{"id":"F10","shared_claims":3},{"id":"F11","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":30},{"id":"F12","shared_claims":14}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T07:00:31.225694Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T07:15:43Z","record_hash":"15e78c5a343f098c6a18c166795a78e6564f22e1bf7df95d69fdc47503fe018d","release_hash":"480aad9887f856ca88a6fe4d6e2bfb0cc6e59b23c8085c3960093518259f4869","report_id":"erudio-nct03784755","run_id":"05dd79cc-356d-4b2d-96fb-ef30e54475dd","schema_version":"5.0","slug":"platon-03784755","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PLATON asks whether adding treatment of metastatic lesions to systemic therapy improves outcomes in hormone-sensitive oligometastatic prostate cancer. Commentary comes from X threads, podcasts and YouTube discussions, with a urologist among the contributors. Debate centers on whether metastasis-directed therapy should be routine care, which endpoints justify its use, and how patient selection should extend beyond technical targetability. Its added contribution alongside contemporary systemic therapy remains an open clinical question.","meta_description":"47 sources screened · 445 verified statements (108 from clinicians verified by NPI or staff page) from 31 sources · 12 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-1e964984e3036d144a17"],"id":"F2","paraphrase":"An X-thread participant asks which outcome PLATON uses as its primary endpoint.","publication_caveats":["Dates are the thread’s post dates.","The exchange concerns trial design, not PLATON efficacy or safety results."],"source_channel":"x_thread","source_date":"2019-10-19","title":"PLATON is valued for testing MDT beyond contemporary systemic therapy, but its clinical impact remains prospective"},{"cited_claim_ids":["claim-e84a08a22e42be45da6d","claim-e0ed47784adc46ab64b7"],"id":"F1","paraphrase":"Within an X-thread discussion mentioning PLATON, a participant asks whether progression-free survival is sufficient to assess metastasis-directed therapy, or whether metastasis-free or overall survival is needed.","publication_caveats":["Dates are the thread’s post dates.","The endpoint question concerns the broader metastasis-directed therapy discussion, not reported PLATON outcomes."],"source_channel":"x_thread","source_date":"2021-04-23","title":"Whether MDT is routine care remains contested, with endpoint choice central to the disagreement"}]},"publication":{"approved_at":"2026-11-01T07:15:43Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":47},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","The source search did not run to completion, so some matching discussion may be missing.","Not yet captured in this edition: a view on guideline-based preference for PSMA PET/CT over conventional imaging when available for metastatic work-up.","Not yet captured in this edition: a view on balancing lesion-directed treatment and androgen deprivation with occupational requirements.","Not yet captured in this edition: a view on oligometastatic eligibility and sequencing systemic treatment with local ablative therapy.","Not yet captured in this edition: a view on insurance denials obstructing both PET and subsequently recommended conventional imaging for treatment work-up.","Not yet captured in this edition: a view on PSMA-guided treatment selection and systemic therapy for PET-detected metastases despite negative conventional imaging.","Not yet captured in this edition: a question about clinical markers and imaging for selecting patients who might benefit from adding lutetium to stereotactic radiotherapy.","Not yet captured in this edition: a view on balancing metastasis-directed therapy and androgen deprivation with occupational needs and trial-dependent systemic intensification.","Not yet captured in this edition: a view on ARPI unsuitability without a stated reason for the assessment.","Not yet captured in this edition: a view on imaging access and funding in staging and treatment selection for oligometastatic prostate cancer.","Not yet captured in this edition: a view on how imaging funding and local access enable PET-first staging and inform treatment choices for occult metastases.","Not yet captured in this edition: a remark on imaging funding and local access conditions preceding treatment decisions for PET-only metastases.","Not yet captured in this edition: a view on lifelong systemic therapy versus metastasis-directed surgery or radiotherapy in hormone-sensitive oligometastatic prostate cancer.","Not yet captured in this edition: a view on retaining ADT as a systemic-treatment option when an ARPI is withheld.","Not yet captured in this edition: a question about focal versus regional nodal irradiation and local-treatment selection when bone metastases coexist.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","204 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion. Source totals, reposts and audience polls cannot establish the number of independent clinicians supporting a position or its prevalence.","Podcast and video versions contain overlapping discussion. Repeated words are not additional agreement, and several passages cannot confidently be assigned to a named speaker.","Discussion not naming PLATON, alternative spellings and other references may be missing. Some relevant passages were not fully assessed, particularly treatment-withholding exceptions, ARPI suitability and administration difficulties, imaging access, and selection or sequencing for lutetium with SBRT.","No separate PLATON protocol document or results publication was identified. Descriptions of its methods, completion and anticipated importance are attributed commentary, not reported efficacy or safety findings.","Evidence from other trials, pooled analyses, presentations and individual patients is not PLATON evidence. Differences in hormone sensitivity, recurrence timing, imaging, systemic treatment and endpoints limit transfer to PLATON's clinical question.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The sources describe two speakers as involved in PLATON. Their views should be read with that source-described involvement, not counted as independent external assessments of the trial.","Versions of the recurrent-patient discussion differ in naming the comparison study as mBARC or EMBARK and in describing whether ADT plus darolutamide was funded. These differences prevent a single confident account of the study analogy or treatment access.","Enrollment numbers and expected timelines vary between statements. Relative completion dates, anticipated readouts and personal forecasts are preserved as expressed and should not be treated as a reconciled trial timeline.","Some brief remarks and treatment terms are unclear. They do not establish a specific regimen, complication treatment, clinical rationale or formal regulatory requirement."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":28,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":31},"count":31,"evidence_window":{"end":"2026-10-08","start":"2018-10-31"},"retrieval_snapshot":"2026-10-31T00:44:40.386274Z","timeline":[{"count":1,"week":"2018-W44"},{"count":1,"week":"2019-W22"},{"count":1,"week":"2019-W38"},{"count":1,"week":"2019-W42"},{"count":1,"week":"2020-W31"},{"count":1,"week":"2020-W53"},{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W16"},{"count":1,"week":"2021-W17"},{"count":1,"week":"2021-W48"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2022-W13"},{"count":1,"week":"2022-W15"},{"count":2,"week":"2022-W19"},{"count":1,"week":"2022-W23"},{"count":1,"week":"2022-W41"},{"count":1,"week":"2023-W18"},{"count":1,"week":"2025-W05"},{"count":2,"week":"2025-W07"},{"count":1,"week":"2025-W41"},{"count":3,"week":"2025-W46"},{"count":2,"week":"2026-W11"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W41"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT03784755:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03784755:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-sx6bg2olo7zncowe67lwhsnw-3lmmw52teu22r","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:03134e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:9fd650","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c75639","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1057663604890185728:1ec02f39-ed93-47af-8ddf-8762ecf32987","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1091667698461933568:27856bac-34ce-4600-81c2-14a5df3c5eec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1132308289520320518:aa663211-b608-4549-a30c-21256b768fa7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1135234856097595393:dacdef9c-8e27-4f6f-98e9-8b65e972afe7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1173616241958891522:f398cb2d-38fe-4fc6-a8aa-b16beefeb483","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1185653011730837504:ef7a16ac-243a-41f8-a889-0be7e9094ce1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1288796065983008770:02e370e6-95c1-4f3c-a41c-27d2d5db2743","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1343977811707650049:4bfdd494-9bd0-47ac-a106-463ed23e34e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1379882303481114624:d2220347-c595-41b4-bfd6-6cfd49348e50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1385528583909744640:2c37b01d-aeb3-438c-b60e-dc17840ce3dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1466685403453296642:c398a734-b079-49f0-9987-b9b980fd75c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1468764681116528643:1f33405b-900f-4838-8b41-7a11994423b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1508923423187120129:1a0e1894-7f0a-45e7-a758-c5bf252f6440","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1514590361951346693:364ab4b3-f6e9-4e25-98a0-0c1205472d02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1524873060276387842:81fe863e-aad1-417e-a612-113dcd79ec62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1524881720587214877:766919cb-0f2b-47ad-9aad-5de505df4a1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1534372103675338752:f9f41dd3-661d-4e9b-918b-bd2f243b0a43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1580152649709936640:cf36966a-2f55-4761-bbcc-693234b7be7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1653374521544437761:b82798ee-4e0e-42b5-b58d-b98c9b725527","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1776532698078617869:3a812b39-092b-4fe1-aeef-9c1e7b77f6a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797385373137375642:f9068296-059b-4f85-928f-7093b7fb8270","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1854275975934021975:e58faf0f-dd92-4d05-8926-1d32d02be92f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1855388170134618444:9934e898-28cc-4d06-8929-1727aa0e7215","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884414450607771675:db723ff0-0954-4fa2-90ee-ac8419d71374","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890184719553425551:7241cb00-58f7-457d-bdad-c7f98de1e167","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890186546244100336:284d80af-9610-4c70-bed3-b60967845c00","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890186682034761853:31facc5e-fe8a-423b-982c-b5dc45f19fa7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890359525691068716:841cf313-506b-41f1-8dea-ad1f0356bce7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1934927755118080352:937c5f06-4720-4282-8399-139df9d0d1f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1989475643017576622:530d017a-1c68-4c24-8260-60438d060afe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1989476441957044381:facda6d5-447b-4dc3-8b3e-b99f64f9a4e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032446813907701962:74248050-47b4-4f73-9689-6f4b88f8c15f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032447016102486110:78a0d1dd-a7d8-4146-96fb-94efb1dbdd44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032479434163249173:351c192d-3fe7-4339-9804-70520b0b7f10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032483185779511798:13b777f0-8562-4a07-a67b-85ab000b2755","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033176052365746447:f0c9d4e4-057d-4735-9ea9-4958166d62cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037514175425945967:8e346b34-caa1-4a8d-9700-22871e7a4a02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049828783444591100:c5b7d9a6-d8c8-4fdc-a758-6e168252ca6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072073952562643351:a8b7c1e0-b99d-4762-9874-dd36786d17e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107153845390286898:cb2af548-9534-4c01-a87b-d3285862a437","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114641569592791472:62acdd24-a277-4c89-990a-28bfcd4fab00","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:CsJZH9ZuERA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:t_5faIN3Dzc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":41,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":47},"count":47,"evidence_window":{"end":"2026-10-26","start":"2018-10-31"},"retrieval_snapshot":"2026-10-31T00:44:40.386274Z","timeline":[{"count":1,"week":"2018-W44"},{"count":1,"week":"2019-W05"},{"count":1,"week":"2019-W21"},{"count":1,"week":"2019-W22"},{"count":1,"week":"2019-W38"},{"count":1,"week":"2019-W42"},{"count":1,"week":"2020-W31"},{"count":1,"week":"2020-W53"},{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W16"},{"count":1,"week":"2021-W17"},{"count":1,"week":"2021-W48"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2022-W13"},{"count":1,"week":"2022-W15"},{"count":2,"week":"2022-W19"},{"count":1,"week":"2022-W23"},{"count":1,"week":"2022-W41"},{"count":1,"week":"2023-W18"},{"count":1,"week":"2023-W27"},{"count":1,"week":"2024-W14"},{"count":1,"week":"2024-W22"},{"count":2,"week":"2024-W45"},{"count":1,"week":"2025-W05"},{"count":4,"week":"2025-W07"},{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W41"},{"count":3,"week":"2025-W46"},{"count":1,"week":"2026-W05"},{"count":5,"week":"2026-W11"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W44"}],"undated_sources":1}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"No mapped registry drugs.","status":"unmapped"},"indications":[{"reason":"Unmapped registry condition: Prostate Cancer Metastatic","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"PLATON","aliases":["PLATON","Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer","A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]"],"brief_title":"Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer","collaborators":["Canadian Cancer Society (CCS)"],"conditions":["Prostate Cancer Metastatic"],"display_condition":"hormone sensitive oligometastatic prostate cancer","display_interventions":[],"enrollment":{"count":409,"type":"ACTUAL"},"interventions":[{"name":"Ablative Radiation Therapy","synonyms":["SBRT","Stereotactic External Beam Irradiation","Stereotactic Radiation Therapy","Stereotactic Radiotherapy"],"type":"RADIATION"},{"name":"Standard of care","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"}],"nct_id":"NCT03784755","official_title":"A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]","overall_status":"ACTIVE_NOT_RECRUITING","phase":["NA"],"primary_completion_date":{"date":"2032-12-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"defined as the time from randomization to the time of the first occurrence.","measure":"Failure-free Survival","timeFrame":"12 years"}],"registered_date":{"date":"2018-12-24","type":"ACTUAL"},"registry_last_updated":"2026-03-27","registry_url":"https://clinicaltrials.gov/study/NCT03784755","short_name":"PLATON","short_name_basis":"registry_acronym","sponsor":"Canadian Cancer Trials Group","start_date":{"date":"2019-11-15","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, na","study_ids":[{"id":"PR20","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}